RegeneRx Biopharmaceuticals (RGRX) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free RGRX Stock Alerts $0.0014 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative November 5, 2023 | morningstar.comRegenerx Biopharmaceuticals Inc RGRXDOctober 31, 2023 | investing.comRegenerx Biopharm In (RGRXD)September 21, 2023 | businesswire.comLIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater ChinaAugust 26, 2023 | seekingalpha.comRGRX RegeneRx Biopharmaceuticals, Inc.August 15, 2023 | finance.yahoo.comRegeneRx Effects Reverse Stock Split and Terminates SEC Reporting ObligationsAugust 8, 2023 | finance.yahoo.comRegeneRx Receives Stockholder Approval for Reverse Stock SplitAugust 1, 2023 | finance.yahoo.comRegeneRx To Extend Consent Solicitation VoteJuly 7, 2023 | thestreet.comBristol-Myers to Split Off Mead JohnsonMay 19, 2023 | thestreet.comPlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage InitiationApril 13, 2023 | finance.yahoo.comFirst Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259April 7, 2023 | marketwatch.comBiopharmaceutical (Biopharma) Aseptic Filling Machine Market Drivers, Risks, Potential Outcomes, and Major Segments for 2030April 7, 2023 | marketwatch.comBiopharmaceutical Third Party Logistics (3PL) Market | 2023-2029March 1, 2023 | marketwatch.com2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028February 24, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 12, 2023 | finance.yahoo.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)January 31, 2023 | finance.yahoo.comThymosin Beta 4 Research Leads Toward Potential Future Anti-aging TherapyJanuary 27, 2023 | markets.businessinsider.com$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are BuyingJanuary 18, 2023 | marketwatch.comBiopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]January 17, 2023 | marketwatch.comBiopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the ReportJanuary 3, 2023 | finance.yahoo.comPublication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic KeratopathyNovember 18, 2022 | finance.yahoo.comBiopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic PartnershipsOctober 24, 2022 | finance.yahoo.comRegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye DiseaseSeptember 30, 2022 | investing.comClover Biopharmaceuticals Ltd (2197)September 27, 2022 | finance.yahoo.comRegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)August 22, 2022 | finance.yahoo.comRegeneRx Issues 2022 Letter To StockholdersJuly 18, 2022 | finance.yahoo.comRegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic KeratitisJune 22, 2022 | finance.yahoo.comRegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259May 4, 2022 | finance.yahoo.comTβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the CorneaFebruary 11, 2022 | finance.yahoo.comRegeneRx Consultant to Receive Prestigious Award for Contributions in Field of HealthFebruary 7, 2022 | nasdaq.comRGRX Real-Time QuotesJanuary 25, 2022 | finance.yahoo.comResearchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol InjuryJanuary 20, 2022 | nasdaq.comRGRX After-Hours QuotesJanuary 12, 2022 | seekingalpha.comMicrocap RegeneRx surges 17% on regulatory development for ophthalmic candidateJanuary 12, 2022 | stockhouse.comRegeneRx Publishes Regulatory Update on RGN-259December 17, 2021 | finance.yahoo.comRegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022November 29, 2021 | finance.yahoo.comRegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye SyndromeOctober 29, 2021 | finance.yahoo.comClinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association MeetingOctober 6, 2021 | finance.yahoo.comResearchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with SepsisOctober 5, 2021 | finance.yahoo.comNew Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's DiseaseSeptember 30, 2021 | yahoo.comBeyond Meat's plant-based 'chicken' tenders are coming to grocery storesSeptember 27, 2021 | finance.yahoo.comRegeneRx Licensee Acquired by Korean Biopharmaceutical GroupJuly 25, 2021 | morningstar.comRegenerx Biopharmaceuticals Inc RGRXJuly 22, 2021 | finance.yahoo.comRegeneRx Issues Letter To Stockholders Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address The CHIPS Act Motherlode (Ad)If you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this. Click here to see my #1 investment for 2024. RGRX Media Mentions By Week RGRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGRX News Sentiment▼0.000.43▲Average Medical News Sentiment RGRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGRX Articles This Week▼00▲RGRX Articles Average Week Get RegeneRx Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Kaleido Biosciences News Bayer Aktiengesellschaft News Capstone News EOM Pharmaceuticals News Genmab A/S News Grifols News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RGRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RegeneRx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
